Levomilnacipran
Serotonin and Norepinephrine Reuptake Inhibitor — NERVOUS SYSTEM
Also known as: fetzima, levomilnacipran HCl, levomilnacipran hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Levomilnacipran is an ofp drug in the Serotonin and Norepinephrine Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors. DrugCentral lists 5 molecular targets, including Slc6a4, SLC6A4 and SLC6A2. Recorded indications include Major depressive disorder.
- Approval status: ofp (first approved 2013 by the FDA).
- Drug class: Serotonin and Norepinephrine Reuptake Inhibitor.
- Mechanism of action: Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors.
- Molecular targets: Slc6a4, SLC6A4, SLC6A2 and SLC6A3 (5 listed in DrugCentral).
- Indications: Major depressive disorder.
- ATC code: N06AX28 (Other antidepressants).
- Molecular formula: C15H22N2O; molecular weight 246.35 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Major depressive disorder
Contraindications (1)
- Angle-closure glaucoma
Mechanism & targets
| Mechanism of action (MoA) | Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors |
|---|---|
| Established pharmacologic class | Serotonin and Norepinephrine Reuptake Inhibitor |
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Sodium-dependent serotonin transporter | Slc6a4 | unknown | Ki 8.07 |
| Sodium-dependent serotonin transporter | SLC6A4 | inhibitor | Ki 7.95 |
| Sodium-dependent noradrenaline transporter | SLC6A2 | inhibitor | Ki 7.04 |
| Sodium-dependent dopamine transporter | SLC6A3 | unknown | IC50 5.49 |
| Glutamate NMDA receptor | Grin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3a | unknown | IC50 5.20 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2013-07-25 | FDA | — | FOREST LABS INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N06AX28 | NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Blepharospasm | 696.0 |
| Taste disorder | 604.5 |
| Epilepsy | 456.7 |
| Infusion site reaction | 440.7 |
| Gastrooesophageal reflux disease | 404.8 |
| Back injury | 342.2 |
| Memory impairment | 298.4 |
| Onychomadesis | 291.0 |
| Peripheral venous disease | 288.4 |
| Breast cancer stage III | 286.3 |
| Product quality issue | 247.3 |
| Paraesthesia | 240.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Levomilnacipran is on its molecule page.
| Molecular formula | C15H22N2O |
|---|---|
| Molecular weight | 246.35 g/mol |
| CAS number | 96847-54-0 |
| InChIKey | GJJFMKBJSRMPLA-DZGCQCFKSA-N |
| PubChem CID | 6917779 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Levomilnacipran used for?
DrugCentral lists the following indications for Levomilnacipran: Major depressive disorder.
How does Levomilnacipran work?
Levomilnacipran is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors; its molecular targets in DrugCentral include Slc6a4, SLC6A4 (inhibitor), SLC6A2 (inhibitor) and SLC6A3.
When was Levomilnacipran first approved?
Levomilnacipran was first approved by the FDA in 2013.
What drug class does Levomilnacipran belong to?
Levomilnacipran is in the Serotonin and Norepinephrine Reuptake Inhibitor class.
What is the chemical formula of Levomilnacipran?
Levomilnacipran has the molecular formula C15H22N2O and a molecular weight of 246.35 g/mol.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4864 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2105732 — compound record and bioactivity
- PubChem CID 6917779 — chemical identifiers
- DrugBank DB08918 — drug record
- FDA UNII UGM0326TXX — substance identity
- DailyMed: FDA labels for Levomilnacipran — current prescribing information (label search)
- UniProt P31645 (SLC6A4) — target protein
- UniProt P23975 (SLC6A2) — target protein
- UniProt Q01959 (SLC6A3) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.